{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T01:02:07Z","timestamp":1780275727299,"version":"3.54.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T00:00:00Z","timestamp":1776470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Liaoning Province Nature Science Foundation","award":["2023-MSLH-157, JYTMS20231829"],"award-info":[{"award-number":["2023-MSLH-157, JYTMS20231829"]}]},{"name":"Shenyang Medical Engineering Cross Research Foundation","award":["22-321-32-09"],"award-info":[{"award-number":["22-321-32-09"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04974-6","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T13:05:33Z","timestamp":1776517533000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of immune microenvironment on immune checkpoint inhibitor response in HER2-overexpressing urothelial carcinoma"],"prefix":"10.1007","volume":"17","author":[{"given":"Ruiyang","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinxu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahe","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangyan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunxian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianshu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bona","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,18]]},"reference":[{"issue":"3","key":"4974_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"Cancer J Clin"},{"key":"4974_CR2","doi-asserted-by":"publisher","first-page":"17022","DOI":"10.1038\/nrdp.2017.22","volume":"3","author":"O Sanli","year":"2017","unstructured":"Sanli O, Dobruch J, Knowles MA, Burger M, Alemozaffar M, Nielsen ME, et al. Bladder cancer. Nat reviews Disease primers. 2017;3:17022. https:\/\/doi.org\/10.1038\/nrdp.2017.22.","journal-title":"Nat reviews Disease primers"},{"issue":"4","key":"4974_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrurol.2017.11","volume":"14","author":"AP Glaser","year":"2017","unstructured":"Glaser AP, Fantini D, Shilatifard A, Schaeffer EM, Meeks JJ. The evolving genomic landscape of urothelial carcinoma. Nat reviews Urol. 2017;14(4):215\u201329. https:\/\/doi.org\/10.1038\/nrurol.2017.11.","journal-title":"Nat reviews Urol"},{"issue":"4","key":"4974_CR4","doi-asserted-by":"publisher","first-page":"216","DOI":"10.6004\/jnccn.2024.0024","volume":"22","author":"TW Flaig","year":"2024","unstructured":"Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, et al. NCCN Guidelines\u00ae Insights: Bladder Cancer, Version 3.2024. J Natl Compr Cancer Network: JNCCN. 2024;22(4):216\u201325. https:\/\/doi.org\/10.6004\/jnccn.2024.0024.","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"issue":"6","key":"4974_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","volume":"35","author":"T Powles","year":"2024","unstructured":"Powles T, Bellmunt J, Comperat E, De Santis M, Huddart R, Loriot Y, et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Annals oncology: official J Eur Soc Med Oncol. 2024;35(6):485\u201390. https:\/\/doi.org\/10.1016\/j.annonc.2024.03.001.","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"10","key":"4974_CR6","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2312117.","journal-title":"N Engl J Med"},{"key":"4974_CR7","doi-asserted-by":"publisher","first-page":"100325","DOI":"10.1016\/j.ctarc.2021.100325","volume":"27","author":"U Swami","year":"2021","unstructured":"Swami U, Grivas P, Pal SK, Agarwal N. Utilization of systemic therapy for treatment of advanced urothelial carcinoma: Lessons from real world experience. Cancer Treat Res Commun. 2021;27:100325. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100325.","journal-title":"Cancer Treat Res Commun"},{"issue":"4717","key":"4974_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1126\/science.2992090","volume":"229","author":"AL Schechter","year":"1985","unstructured":"Schechter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, et al. The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Sci (New York NY). 1985;229(4717):976\u20138. https:\/\/doi.org\/10.1126\/science.2992090.","journal-title":"Sci (New York NY)"},{"key":"4974_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev.cb.10.110194.001343","volume":"10","author":"P van der Geer","year":"1994","unstructured":"van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol. 1994;10:251\u2013337. https:\/\/doi.org\/10.1146\/annurev.cb.10.110194.001343.","journal-title":"Annu Rev Cell Biol"},{"issue":"8","key":"4974_CR10","doi-asserted-by":"publisher","first-page":"e617","DOI":"10.1093\/oncolo\/oyad070","volume":"28","author":"L Zhou","year":"2023","unstructured":"Zhou L, Shao Z, Liu Y, Yan X, Li J, Wu X, et al. HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population. Oncologist. 2023;28(8):e617\u201324. https:\/\/doi.org\/10.1093\/oncolo\/oyad070.","journal-title":"Oncologist"},{"key":"4974_CR11","doi-asserted-by":"publisher","first-page":"1011885","DOI":"10.3389\/fonc.2022.1011885","volume":"12","author":"E Scherrer","year":"2022","unstructured":"Scherrer E, Kang A, Bloudek LM, Koshkin VS. HER2 expression in urothelial carcinoma, a systematic literature review. Front Oncol. 2022;12:1011885. https:\/\/doi.org\/10.3389\/fonc.2022.1011885.","journal-title":"Front Oncol"},{"issue":"8","key":"4974_CR12","first-page":"2440","volume":"7","author":"RE Jimenez","year":"2001","unstructured":"Jimenez RE, Hussain M, Bianco FJ Jr., Vaishampayan U, Tabazcka P, Sakr WA, et al. Her-2\/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin cancer research: official J Am Association Cancer Res. 2001;7(8):2440\u20137.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"8","key":"4974_CR13","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1038\/s41379-018-0023-9","volume":"31","author":"A Moktefi","year":"2018","unstructured":"Moktefi A, Pouessel D, Liu J, Sirab N, Maille P, Soyeux P, et al. Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. Mod pathology: official J United States Can Acad Pathol Inc. 2018;31(8):1270\u201381. https:\/\/doi.org\/10.1038\/s41379-018-0023-9.","journal-title":"Mod pathology: official J United States Can Acad Pathol Inc"},{"issue":"6","key":"4974_CR14","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/cam4.432","volume":"4","author":"J Bellmunt","year":"2015","unstructured":"Bellmunt J, Werner L, Bamias A, Fay AP, Park RS, Riester M, et al. HER2 as a target in invasive urothelial carcinoma. Cancer Med. 2015;4(6):844\u201352. https:\/\/doi.org\/10.1002\/cam4.432.","journal-title":"Cancer Med"},{"key":"4974_CR15","doi-asserted-by":"publisher","unstructured":"Wan X, Wang D, Zhang X, Xu M, Huang Y, Qin W, et al. Unleashing the power of urine\u2013based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review). Int J Oncol. 2025;66(3). https:\/\/doi.org\/10.3892\/ijo.2025.5724.","DOI":"10.3892\/ijo.2025.5724"},{"issue":"1","key":"4974_CR16","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12967-025-06323-7","volume":"23","author":"J Brea-Iglesias","year":"2025","unstructured":"Brea-Iglesias J, Gallardo-G\u00f3mez M, Oitab\u00e9n A, L\u00e1zaro-Quintela ME, Le\u00f3n L, Alves JM, et al. Genomics guiding personalized first-line immunotherapy response in lung and bladder tumors. J translational Med. 2025;23(1):404. https:\/\/doi.org\/10.1186\/s12967-025-06323-7.","journal-title":"J translational Med"},{"issue":"22","key":"4974_CR17","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1093\/ajhp\/zxae090","volume":"81","author":"RJ Cersosimo","year":"2024","unstructured":"Cersosimo RJ. Targeted and immunotherapy for the management of advanced urothelial carcinoma of the bladder. Am J health-system pharmacy: AJHP : official J Am Soc Health-System Pharmacists. 2024;81(22):1109\u201323. https:\/\/doi.org\/10.1093\/ajhp\/zxae090.","journal-title":"Am J health-system pharmacy: AJHP : official J Am Soc Health-System Pharmacists"},{"issue":"3","key":"4974_CR18","doi-asserted-by":"publisher","first-page":"110970","DOI":"10.1016\/j.urolonc.2025.12.006","volume":"44","author":"M Qu","year":"2026","unstructured":"Qu M, Wei J, Mo J, Chen J, Wu X, Xu H, et al. Disitamab vedotin with or without PD-1 inhibitors in pretreated patients with locally advanced or metastatic urothelial carcinoma: Identifying patients who derive additional benefit from immune combination therapy. Urol Oncol. 2026;44(3):110970. https:\/\/doi.org\/10.1016\/j.urolonc.2025.12.006.","journal-title":"Urol Oncol"},{"issue":"1","key":"4974_CR19","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1038\/s41467-021-23053-8","volume":"12","author":"W Shi","year":"2021","unstructured":"Shi W, Zhang G, Ma Z, Li L, Liu M, Qin L, et al. Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer. Nat Commun. 2021;12(1):2812. https:\/\/doi.org\/10.1038\/s41467-021-23053-8.","journal-title":"Nat Commun"},{"key":"4974_CR20","doi-asserted-by":"publisher","unstructured":"Kavarthapu R, Anbazhagan R, Dufau ML. Crosstalk between PRLR and EGFR\/HER2 Signaling Pathways in Breast Cancer. Cancers. 2021;13(18). https:\/\/doi.org\/10.3390\/cancers13184685.","DOI":"10.3390\/cancers13184685"},{"issue":"1","key":"4974_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/1078-0432.Ccr-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng X, Yan X, Wang L, Shi Y, Yao X, Luo H, et al. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody-Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma. Clin cancer research: official J Am Association Cancer Res. 2021;27(1):43\u201351. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2488.","journal-title":"Clin cancer research: official J Am Association Cancer Res"},{"issue":"12","key":"4974_CR22","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1200\/jco.22.02912","volume":"42","author":"X Sheng","year":"2024","unstructured":"Sheng X, Wang L, He Z, Shi Y, Luo H, Han W, et al. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials. J Clin oncology: official J Am Soc Clin Oncol. 2024;42(12):1391\u2013402. https:\/\/doi.org\/10.1200\/jco.22.02912.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"38","key":"4974_CR23","doi-asserted-by":"publisher","first-page":"63901","DOI":"10.18632\/oncotarget.19194","volume":"8","author":"KJ Suh","year":"2017","unstructured":"Suh KJ, Sung JH, Kim JW, Han SH, Lee HS, Min A, et al. EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. Oncotarget. 2017;8(38):63901\u201310. https:\/\/doi.org\/10.18632\/oncotarget.19194.","journal-title":"Oncotarget"},{"issue":"7","key":"4974_CR24","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. https:\/\/doi.org\/10.1093\/nar\/gkv007.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"4974_CR25","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"OMICS"},{"issue":"43","key":"4974_CR26","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4974_CR27","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. https:\/\/doi.org\/10.1038\/ncomms3612.","journal-title":"Nat Commun"},{"issue":"5","key":"4974_CR28","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453\u20137. https:\/\/doi.org\/10.1038\/nmeth.3337.","journal-title":"Nat Methods"},{"issue":"31","key":"4974_CR29","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/jco.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin oncology: official J Am Soc Clin Oncol. 2013;31(31):3997\u20134013. https:\/\/doi.org\/10.1200\/jco.2013.50.9984.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"3","key":"4974_CR30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171(3):540\u2013e5625. https:\/\/doi.org\/10.1016\/j.cell.2017.09.007.","journal-title":"Cell"},{"issue":"1","key":"4974_CR31","doi-asserted-by":"publisher","first-page":"7959","DOI":"10.1038\/s41467-022-35649-9","volume":"13","author":"L Sui","year":"2022","unstructured":"Sui L, Wang S, Ganguly D, El Rayes TP, Askeland C, B\u00f8rretzen A, et al. PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression. Nat Commun. 2022;13(1):7959. https:\/\/doi.org\/10.1038\/s41467-022-35649-9.","journal-title":"Nat Commun"},{"issue":"2","key":"4974_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.jncc.2023.02.003","volume":"3","author":"H Lei","year":"2023","unstructured":"Lei H, Ling Y, Yuan P, Yan X, Wang L, Shi Y, et al. Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer. J Natl Cancer Cent. 2023;3(2):121\u20138. https:\/\/doi.org\/10.1016\/j.jncc.2023.02.003.","journal-title":"J Natl Cancer Cent"},{"key":"4974_CR33","doi-asserted-by":"publisher","unstructured":"Sanguedolce F, Zanelli M, Palicelli A, Bisagni A, Zizzo M, Ascani S, et al. HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role. Int J Mol Sci. 2023;24(4). https:\/\/doi.org\/10.3390\/ijms24043720.","DOI":"10.3390\/ijms24043720"},{"issue":"5","key":"4974_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s11523-025-01165-1","volume":"20","author":"F Ciciriello","year":"2025","unstructured":"Ciciriello F, Pezzicoli G, Biasi A, D\u2019Addario C, Salonne F, Porta C, et al. HER2-Positive Urothelial Carcinoma: Current Evidence on Targeted Agents and Immunotherapy-Based Combinations. Target Oncol. 2025;20(5):755\u201365. https:\/\/doi.org\/10.1007\/s11523-025-01165-1.","journal-title":"Target Oncol"},{"key":"4974_CR35","doi-asserted-by":"publisher","unstructured":"Melssen MM, Sheybani ND, Leick KM, Slingluff CL. Jr. Barriers to immune cell infiltration in tumors. J Immunother Cancer. 2023;11(4). https:\/\/doi.org\/10.1136\/jitc-2022-006401.","DOI":"10.1136\/jitc-2022-006401"},{"issue":"23","key":"4974_CR36","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","volume":"393","author":"X Sheng","year":"2025","unstructured":"Sheng X, Zeng G, Zhang C, Zhang Q, Bian J, Niu H, et al. Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. N Engl J Med. 2025;393(23):2324\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2511648.","journal-title":"N Engl J Med"},{"key":"4974_CR37","doi-asserted-by":"publisher","unstructured":"Raftery NB, Ward M, Ravi N, Reynolds JV, Elliott JA, Donohoe CL. Modulation of the Tumour Microenvironment by HER2 in Oesophagogastric Adenocarcinoma: Implications for Tumour Progression, Therapeutic Resistance, and Clinicopathological Outcomes. Cancers. 2025;17(24). https:\/\/doi.org\/10.3390\/cancers17243987.","DOI":"10.3390\/cancers17243987"},{"issue":"1","key":"4974_CR38","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58\u201367. https:\/\/doi.org\/10.1182\/blood-2017-06-741033.","journal-title":"Blood"},{"issue":"9","key":"4974_CR39","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.7150\/jca.57334","volume":"12","author":"C Ghosh","year":"2021","unstructured":"Ghosh C, Luong G, Sun Y. A snapshot of the PD-1\/PD-L1 pathway. J Cancer. 2021;12(9):2735\u201346. https:\/\/doi.org\/10.7150\/jca.57334.","journal-title":"J Cancer"},{"issue":"2","key":"4974_CR40","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.18632\/oncotarget.13895","volume":"8","author":"Y Dong","year":"2017","unstructured":"Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8(2):2171\u201386. https:\/\/doi.org\/10.18632\/oncotarget.13895.","journal-title":"Oncotarget"},{"issue":"5","key":"4974_CR41","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1093\/intimm\/8.5.765","volume":"8","author":"Y Agata","year":"1996","unstructured":"Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996;8(5):765\u201372. https:\/\/doi.org\/10.1093\/intimm\/8.5.765.","journal-title":"Int Immunol"},{"issue":"7","key":"4974_CR42","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41416-022-02084-y","volume":"128","author":"Y Wang","year":"2023","unstructured":"Wang Y, Du J, Gao Z, Sun H, Mei M, Wang Y, et al. Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy. Br J Cancer. 2023;128(7):1196\u2013207. https:\/\/doi.org\/10.1038\/s41416-022-02084-y.","journal-title":"Br J Cancer"},{"key":"4974_CR43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.20517\/cdr.2023.46","volume":"7","author":"P Spiliopoulou","year":"2024","unstructured":"Spiliopoulou P, Kaur P, Hammett T, Di Conza G, Lahn M, Targeting T. regulatory (T(reg)) cells in immunotherapy-resistant cancers. Cancer drug Resist (Alhambra Calif). 2024;7:2. https:\/\/doi.org\/10.20517\/cdr.2023.46.","journal-title":"Cancer drug Resist (Alhambra Calif)"},{"issue":"1","key":"4974_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-021-06384-4","volume":"191","author":"L Huang","year":"2022","unstructured":"Huang L, Wang R, Xie K, Zhang J, Tao F, Pi C, et al. A HER2 target antibody drug conjugate combined with anti-PD-(L)1 treatment eliminates hHER2\u2009+\u2009tumors in hPD-1 transgenic mouse model and contributes immune memory formation. Breast Cancer Res Treat. 2022;191(1):51\u201361. https:\/\/doi.org\/10.1007\/s10549-021-06384-4.","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"4974_CR45","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s00262-023-03419-1","volume":"72","author":"M Chen","year":"2023","unstructured":"Chen M, Yao K, Cao M, Liu H, Xue C, Qin T, et al. HER2-targeting antibody-drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study. Cancer Immunol immunotherapy: CII. 2023;72(7):2309\u201318. https:\/\/doi.org\/10.1007\/s00262-023-03419-1.","journal-title":"Cancer Immunol immunotherapy: CII"},{"key":"4974_CR46","doi-asserted-by":"publisher","first-page":"111693","DOI":"10.1016\/j.ecoenv.2020.111693","volume":"208","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Jin P, Liu J, Li S, Liu W, Xi S. HER2 overexpression triggers the IL-8 to promote arsenic-induced EMT and stem cell-like phenotypes in human bladder epithelial cells. Ecotoxicol Environ Saf. 2021;208:111693. https:\/\/doi.org\/10.1016\/j.ecoenv.2020.111693.","journal-title":"Ecotoxicol Environ Saf"},{"key":"4974_CR47","doi-asserted-by":"publisher","first-page":"1301510doi","DOI":"10.3389\/fimmu.2023.1301510","volume":"14","author":"W Nam","year":"2023","unstructured":"Nam W, Chae HK, Jung Y, Kang H, Park M, Choi A, et al. HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer. Front Immunol. 2023;14:1301510doi. https:\/\/doi.org\/10.3389\/fimmu.2023.1301510.","journal-title":"Front Immunol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04974-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04974-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04974-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:49:32Z","timestamp":1780274972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04974-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,18]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4974"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04974-6","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,18]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the principles of the Declaration of Helsinki and relevant national and institutional guidelines. The study protocol was reviewed and approved by the Ethics Committee of the General Hospital of Northern Theater Command (Approval No. k2025279). All procedures performed in this study involving human participants were carried out in accordance with the ethical standards of the above-mentioned committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. All data presented in this study were fully anonymized, and no identifiable personal information is included.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"826"}}